NCT00800462

Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: Toronto Rehabilitation Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.

Conditions

• Spinal Cord Injury
• Neurogenic Detrusor Overactivity

Interventions

Type	Name	Description
DRUG	Oxybutynin Cl	15 mg qd for 3 months
DRUG	Trospium Cl	20mg bid for 3 months
DRUG	Darifenacin Hydrogen Bromide (HBr)	15 mg qd for 3 months

Timeline

• Start date: 2008-03-01
• Primary completion: 2012-06-01
• Completion: 2012-12-01
• First posted: 2008-12-02
• Last updated: 2013-04-08

Locations

2 sites across 1 country: Canada